2seventy bio | 10-Q: Quarterly report
2seventy Bio Is Maintained at Buy by Canaccord Genuity
2seventy Bio Is Maintained at Buy by Canaccord Genuity
Canadian Investment Banking Group: Maintaining the 2seventy bio (TSVT.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
Canadian Investment Banking Group: Maintaining the 2seventy bio (TSVT.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
Canaccord Genuity Maintains Buy on 2seventy Bio, Lowers Price Target to $11
Canaccord Genuity analyst John Newman maintains 2seventy bio (NASDAQ:TSVT) with a Buy and lowers the price target from $12 to $11.
2seventy Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 148.31% Canaccord Genuity $12 → $11 Maintains Buy 04/08/2024 170.88% Citigroup $9 → $12 Maintai
2seventy Bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call Transcript
Q1 2024 2Seventy Bio Inc Earnings Call
2seventy Bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript
2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript
2seventy Bio Inc (TSVT) Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Realignments
2seventy Bio Q1 Adj $(0.81), Inline, Sales $12.44M Miss $14.08M Estimate
2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(1.08) per share from the same period
2seventy Bio 1Q Loss $52.7M >TSVT
2seventy Bio 1Q Loss $52.7M >TSVT
2seventy Bio 1Q Rev $12.4M >TSVT
2seventy Bio 1Q Rev $12.4M >TSVT
2seventy Bio 1Q Loss/Shr $1.01 >TSVT
2seventy Bio 1Q Loss/Shr $1.01 >TSVT
Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, Vs. Street Est of $14.1M
07:02 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M
Press Release: 2seventy Bio Reports First Quarter Financial Results and Recent Operational Progress
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines
2seventy Bio to Report First Quarter 2024 Financial Results on May 8, 2024
2seventy bio, Inc. (NASDAQ:TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference
Leerink Partners Sticks to Their Buy Rating for 2seventy Bio (TSVT)
Bristol-Myers Posts Q1 Beat Despite Growth Headwinds
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-related caution for medications—for all chimeric antige
FDA Requires Labeling Changes to CAR-T Cell Therapies to Reflect Cancer Risk
No Data